Bringing the promise of genetic medicine to children with rare disease

At LogicBio, we are committed to delivering genetic medicine to pediatric patients with rare diseases.

We are initially targeting rare liver disorders where it is critically important to treat patients early in life, before irreversible damage occurs. We believe our foundational platform technology, GeneRide, is well-suited to this goal because – unlike traditional gene therapy – it harnesses the cell’s natural DNA repair process to integrate a corrective gene directly into the patient’s chromosomes. This approach is designed to provide a durable therapeutic benefit from a single treatment.

Our team is comprised of global leaders in gene therapy and gene editing.

We are passionate, driven and fiercely committed to developing the next generation of genetic medicines.

We are here to make a difference.

Leadership team

Fred Chereau

President and Chief Executive Officer

Dean Falb, Ph.D.

Chief Scientific Officer

Matthias Jaffé

Chief Financial Officer

Tom Wilton

Chief Business Officer

Kenneth Huttner, M.D., Ph.D.

SVP, Head of Clinical Development

Nelson Chau, Ph.D.

VP, Biology & Translational Research

Kyle Chiang, Ph.D.

VP, Product Strategy

Matthias Hebben, Ph.D.

VP, Technology Development

Marie Payton

VP, Clinical Operations

Carol Sherako

Sr. Director, Program Management

Scientific founders

Mark Kay, M.D., Ph.D.

Click for bio

Adi Barzel, Ph.D.

Click for bio

Leszek Lisowski, Ph.D., MBA

Click for bio

Board members

Leon Chen, Ph.D.

Click for bio

Frederic Chereau, MBA

Click for bio

Erez Chimovits, MBA

Click for bio

Tomer Kariv, J.D.

Click for bio

Mark Kay, M.D., Ph.D.

Click for bio

Richard Moscicki, M.D.,

Click for bio

Daniel O’Connell, M.D., Ph.D.

Click for bio

Michael Wyzga

Click for bio